Catheter ablation in end-stage heart failure with atrial fibrillation: two-year follow-up of the CASTLE-HTx trial

30 August 2024 (16:39 - 16:51)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Professor Christian Sohns

Heart and Diabetes Center NRW, Bad Oeynhausen (Germany)

4 More presentations in this session

Presentation thumbnail

The effect of dapagliflozin on accelerometer-based measures of physical activity in heart failure: an exploratory analysis of the DETERMINE trials

Doctor K. Docherty (Glasgow, GB)

Presentation thumbnail

Synchronized left ventricular pacing improves cardiac resynchronization therapy outcomes: insights from AdaptResponse

Doctor D. Birnie (Ottawa, CA)

Presentation thumbnail

A randomised, double-blind, placebo-controlled study to investigate the safety and tolerability of XXB750 in heart failure patients with reduced or mildly reduced ejection fraction

Doctor T. Hauser (Cambridge, US)

Presentation thumbnail

Rapid detection of incident heart failure by artificial intelligence: lessons from the NIL-CHF trial

Professor S. Stewart (Fremantle, AU)

Access the full session

Session thumbnail

Smaller trials, trial updates, and other studies on heart failure (1)

The Event

Event poster

ESC Congress 2024

30 August 2024 16:39 CET

You may be interested in

Congress Presentation

Main 3-Year Outcomes of CASTLE-HTx

Congress Presentation

Prognosis of patients in end-stage heart failure with atrial fibrillation treated with ablation - Insights from Castle HTX

Congress Presentation

CASTLE-HTx: Catheter Ablation versus Medical Therapy to Treat Atrial Fibrillation in End-stage Heart Failure

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources